These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23726723)

  • 21. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Once- Versus Twice-Daily Tacrolimus Dosing on Medication Adherence in Stable Renal Transplant Recipients: A Canadian Single-Center Randomized Controlled Trial.
    Paterson TSE; Demian M; Shapiro RJ; Loken Thornton W
    Can J Kidney Health Dis; 2019; 6():2054358119867993. PubMed ID: 31452902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once daily tacrolimus conversion in lung transplantation: A prospective study on safety and medication adherence.
    Godinas L; Dobbels F; Hulst L; Verbeeck I; De Coninck I; Berrevoets P; Schaevers V; Yserbyt J; Dupont LJ; Verleden SE; Vanaudenaerde BM; Ceulemans LJ; Van Raemdonck DE; Neyrinck A; Verleden GM; Vos R
    J Heart Lung Transplant; 2021 Jun; 40(6):467-477. PubMed ID: 33840608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: A randomized prospective study.
    Kim JM; Kwon CH; Joh JW; Sinn DH; Lee S; Choi GS; Lee SK
    Liver Transpl; 2016 Feb; 22(2):209-16. PubMed ID: 26360125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L
    Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion From Twice-Daily to Once-Daily Tacrolimus Among Egyptian Living-Donor Kidney Allograft Recipients: A Single-Center Experience.
    Bakr MA; Nagib AM; Abbas MH; Donia AF
    Exp Clin Transplant; 2019 Oct; 17(5):594-598. PubMed ID: 31050617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
    Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
    J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing.
    Hardinger KL; Park JM; Schnitzler MA; Koch MJ; Miller BW; Brennan DC
    Am J Transplant; 2004 Apr; 4(4):621-5. PubMed ID: 15023155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
    Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
    Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion from twice-daily to once-daily tacrolimus in stable liver transplant patients: effectiveness in a real-world setting.
    Valente G; Rinaldi L; Sgambato M; Piai G
    Transplant Proc; 2013 Apr; 45(3):1273-5. PubMed ID: 23622676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.
    Florman S; Alloway R; Kalayoglu M; Lake K; Bak T; Klein A; Klintmalm G; Busque S; Brandenhagen D; Lake J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):1211-3. PubMed ID: 15848672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-adherence and graft failure in adult liver transplant recipients.
    Lieber SR; Volk ML
    Dig Dis Sci; 2013 Mar; 58(3):824-34. PubMed ID: 23053889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus.
    Kurnatowska I; Krawczyk J; Oleksik T; Nowicki M
    Transplant Proc; 2011 Oct; 43(8):2954-6. PubMed ID: 21996199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation on the simplified medication adherence questionnaire (SMAQ) in renal transplant patients on tacrolimus.
    Ortega Suárez FJ; Sánchez Plumed J; Pérez Valentín MA; Pereira Palomo P; Muñoz Cepeda MA; Lorenzo Aguiar D;
    Nefrologia; 2011; 31(6):690-6. PubMed ID: 22130285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients.
    Comuzzi C; Lorenzin D; Rossetto A; Faraci MG; Nicolini D; Garelli P; Bresadola V; Toniutto P; Soardo G; Baroni GS; Adani GL; Risaliti A; Baccarani U
    Transplant Proc; 2010 May; 42(4):1320-1. PubMed ID: 20534291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Kidney Graft Recipients.
    Barreto P; Malheiro J; Vieira P; Pedroso S; Almeida M; Martins LS; Dias L; Henriques AC; Cabrita A
    Transplant Proc; 2016 Sep; 48(7):2276-2279. PubMed ID: 27742278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
    Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
    Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety Evaluation After Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplant Recipients: A Phase 4, Open-Label, Single-Center Study.
    Kang WH; Song GW; Moon DB; Hwang S; Kim KH; Jung DH; Park GC; Yoon YI; Cho HD; Kim M; Kim SH; Na BG; Kim SM; Yang G; Lee SG
    Transplant Proc; 2021 Dec; 53(10):3000-3006. PubMed ID: 34776265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A; Poli L; Nofroni I; Bachetoni A; Tinti F; Umbro I; Barile M; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
    DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.